LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
NCT03684980
Recruiting
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +10 locations
Conditions: Central Nervous System Lymphoma
Register for Updates
Steroids and Pain Control After Tonsillectomy
NCT03995628
Recruiting
This research study aims to find out if a single oral dose of steroid after tonsillectomy will reduce pain and decrease the need for narcotic medications.
Gender:
ALL
Ages:
Between 3 years and 12 years
Trial Updated:
07/21/2025
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Tonsillitis, Obstructive Sleep Apnea of Child
Register for Updates
Progressive Abduction Loading Therapy
NCT04118998
Recruiting
This study attempts to minimize the development of a common movement impairment following stroke known as "flexion synergy" that makes it extremely difficult to reach outward with the arm. Participants with acute/subacute stroke will receive one of two study interventions in addition to prescribed therapies in both inpatient rehabilitation and day-rehab. Participants will be followed for 1 year.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/21/2025
Locations: Department of Physical Therapy and Human Movement Sciences, Chicago, Illinois +2 locations
Conditions: Stroke, Acute
Register for Updates
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
NCT04207619
Recruiting
Hypoglycemic complications are a major impediment to the maintenance of healthy glucose levels in persons with diabetes. The investigators recently completed a clinical pilot and feasibility study (GLIMPSE, NCT02690168), which identified a novel biomarker, glial acetate metabolism, that appears to predict the susceptibility to hypoglycemia. By providing an assay to predict hypoglycemic events and therefore diabetic complications, the development of this biomarker could significantly improve the... Read More
Gender:
ALL
Ages:
Between 18 years and 40 years
Trial Updated:
07/21/2025
Locations: Pennington Biomedical Research Center, Baton Rouge, Louisiana
Conditions: Diabetes, Hypoglycemia
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
07/21/2025
Locations: University of Alabama, Children's Alabama, Birmingham, Alabama +28 locations
Conditions: Neuroblastoma
Register for Updates
A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis
NCT04368806
Recruiting
This study is a double-blind, randomized, placebo controlled, multi-center, superiority study to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a 2-week screening period, approximately 140 subjects will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes 48-Weeks visit (Visit 8) and the data management... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: TriWest Research Associates, El Cajon, California +8 locations
Conditions: Osteoarthritis, Knee
Register for Updates
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NCT04421560
Recruiting
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed Cancer
Register for Updates
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
NCT04482309
Recruiting
This is an open-label, multi-center, multi-cohort, Phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for the treatment of selected HER2-expressing tumors. This study will consist of Part 1 which includes 7 cohorts of: urothelial bladder cancer, biliary tract cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and rare tumors; and Part 2 which includes 5 cohorts A to E of: A) any tumor type that is HER2 IHC 3+ (excluding breast, gastr... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/21/2025
Locations: Research Site, Burbank, California +122 locations
Conditions: Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
Register for Updates
Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
NCT04627428
Recruiting
The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/21/2025
Locations: Retina Vitreous Associates Medical Group, Beverly Hills, California +2 locations
Conditions: Dry Age-related Macular Degeneration
Register for Updates
Secondhand Tobacco Smoke and Cardiovascular Disease
NCT04715568
Recruiting
This is a double-blind randomized placebo-controlled crossover clinical trial of efficacy and safety of an FDA-approved angiotensin receptor blocker (losartan) to improve cardiopulmonary outcomes in individuals with pre-Chronic Obstructive Pulmonary Disease (COPD) due to prolonged exposure to secondhand tobacco smoke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/21/2025
Locations: San Francisco Veterans' Affairs Medical Center, San Francisco, California
Conditions: Cardiovascular Diseases, Hypertension
Register for Updates
Retina is a Marker for Cerebrovascular Heath
NCT04753970
Recruiting
Cerebral small vessel disease (SVD), present in 80-94% of adults over age 65 years, increases the risk of stroke by 2-fold, and dementia by 2.3-fold. There is currently no treatment to slow SVD progression. This study aims to test whether impaired cerebral and retinal vasoreactivity may serve as biomarker for SVD progression, and to evaluate the safety and efficacy of cilostazol (antiplatelet agent with vasodilatory and anti-inflammatory properties) for the treatment of SVD.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/21/2025
Locations: Mayo Clinic Florida, Jacksonville, Florida
Conditions: Cerebral Small Vessel Diseases, Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy, Cerebral Microbleeding, Sporadic White Matter Disease
Register for Updates
Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism
NCT04790370
Recruiting
There are many available treatments for pulmonary embolism (PE), but the best treatment for this condition is not known. The HI-PEITHO study will compare two treatment options that are both available on the market for the treatment of PE. Patients will be randomized 1:1 to receive either blood thinners (anticoagulation) or blood thinners (anticoagulation) in combination with a device called the EkoSonicTM Endovascular device to dissolve blood clots. Patients will be followed for 12 months after... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
07/21/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +71 locations
Conditions: Pulmonary Embolism
Register for Updates